Spending on medicines in Israel in an international context

Israel Medical Association Journal

Volumn 7, Issue 5, 2005, Pages 286-291

  Sax, Philip ^a,b  

^a PHARMA   (Israel)

^b NONE   (Israel)

Author keywords

Cost containment; Drug expenditure; Drug policy; International comparison; Israel

Indexed keywords

ARTICLE; COST CONTROL; DRUG COST; DRUG MARKETING; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; ISRAEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

DEVELOPED COUNTRIES; DRUG COSTS; DRUG UTILIZATION; FEES, PHARMACEUTICAL; HEALTH EXPENDITURES; HUMANS; INTERNATIONAL AGENCIES; INTERNATIONALITY; ISRAEL; TIME FACTORS;

EID: 18744363647     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Israel's Social Services 2001-2. Kop Y. ed. Jerusalem: The Center for Social Policy Studies in Israel, 2002.
2. Report of decisions made at a government meeting to discuss economic policy for 2005, 15 August 2004. Prime Minister's Office, Jerusalem.
3. Sax P. Recent trends in drug utilization in Israel. Isr J Med Sci 1992;28:718-25.
4. Sax P. Expenditure and consumption of medicines in Israel 1975-85: analysis of trends and elements of growth. Isr J Med Sci 1988;24:307-16.
5. Sax P. Changes in drug economy in Israel's health maintenance organizations in the wake of the National Health Insurance Law. IMAJ 2001;3:605-9.
6. Sax P. The drug economy during period of updating the basket: analysis and policy implications. Pharma Israel Drug Bull 2003;54B:1-4.
7. Sax P. More drugs, more revenues, less benefits: sick funds and their members. Pharma Israel Drug Bull 2004;58B:1-2.
8. Annual reports of activities of sick funds. Jerusalem: Ministry of Health, 1992 and 1997-2002 (Hebrew).
9. Family Expenditure Survey. Jerusalem: Central Bureau of Statistics, 1992/3-2002 (Hebrew).
10. Health data. Paris: OECD, 2004 (1st edition).
11. National expenditure on health. Jerusalem: Central Bureau of Statistics, 1992-2002.
12. Miller RD, Frech HE. Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 2000;18(Suppl 1):33-45.
13. Sax P. Assessing national drug price levels and trends: The case of Israel. J Soc Admin Pharm 1991;8:164-74.
14. Mossialos E. Regulating expenditure on medicines in European Union countries. In: Saltman RB, Figueras I, Sakellarides C, eds. Critical Challenges for Health Care Reform in Europe. Buckingham, UK: WHO and Open University Press, 2000:261-6.
15. Ess SM, Schneeweiss S, Szcics TD. European health care policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89-103.
16. Pierson P. Dismantling the Welfare State? Reagan, Thatcher and the Politics of Retrenchment. Cambridge, UK: Cambridge University Press, 1994:132-9.
17. Pharma Marketletter. German fixed-level price support for statins. 16 August 2004:10.
18. Reuveni H, Sheizaf B, Ellhayany A. The effect of drug co-payment policy on the purchase of prescription drugs for children with infections in the community. Health Policy 2002;62:1-13.
19. Bentur N, Gross R, Brammli-Greenberg S. Satisfaction wth access to community care of the chronically ill in Israel's health-care system. Health Policy 2004;67:129-36.
20. Bramli-Greenberg S, Rosen B, Wood F. Households, health plans and expenditures for medications. Jerusalem: JDC-Brookdale Institute. April 2003
21. Heisler M, Langa KM, Eby EL. The health effects of restricting prescription medication use because of costs. Med Care 2004;42:626-34.
22. Pharma Marketletter. New Zealand: 3-year pharma funding path. 13 September 2004.